Caplin Point Laboratories Ltd.

₹1,565.8

-4.3 (-0.3%)

CAPLIPOINT Share Price

Pharmaceuticals & Biotechnology

As on April 2, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 11,961 Cr

P/E Ratio22.19

Dividend Yield0.19 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,558.94	Bullish
10-DMA	1,581.54	Bearish
20-DMA	1,622.49	Bearish
50-DMA	1,701.21	Bearish
100-DMA	1,801.21	Bearish
200-DMA	1,944.57	Bearish

Historical Performance

1 Year

-20.8%

3 Years

162.7%

5 Years

246.1%

10 Years

621.4%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	19,375	16,941	14,667	12,694	10,613
Total Expenditure	12,905	11,427	10,262	8,749	7,370
Other Income	964	669	565	389	279
Operating Profit	7,434	6,184	4,970	4,334	3,522
Interest	6	8	8	7	16
Depreciation	660	534	450	469	370
Profit Before Tax	6,768	5,644	4,514	3,858	3,136
Consolidated Net Profit	5,363	4,571	3,763	2,998	2,423
Adjusted EPS	71	60	50	40	32

Compounded Sales Growth

10 Years:50.4

5 Years:17.6

3 Years:8.8

TTM:2.7

Compounded Profit Growth

10 Years:67.2

5 Years:20.1

3 Years:12.3

TTM:3.2

Stock Price CAGR

10 Years:21.9

5 Years:28.2

3 Years:36.9

TTM:-23.8

Return on Equity

10 Years:6.1

5 Years:32

3 Years:49.6

last year:70.6

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	898	898	898	897	897
Total Reserves	27,411	22,117	17,753	13,787	10,813
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	132	79	21	126	174
Other Current Liabilities	643	903	999	487	519
Short Term Borrowings	6	3	34	5	---
Total Liabilities	32,056	26,856	21,774	17,301	13,636
Capital Work in Progress	1,392	1,166	2,205	154	138
Long Term Loans & Advances	886	783	515	899	79
Currents Investments	3,113	2,380	2,102	520	105
Short Term Loans and Advances	1,855	1,460	1,434	2,249	871
Total Current Assets	21,339	18,929	15,522	12,978	10,146
Total Assets	32,056	26,856	21,774	17,301	13,636
Adjusted Book Value	363	293	236	184	145

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 22.19, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 36.9%, indicating sustained price appreciation.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹7434 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹19375 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 761724.1

No. of Shares: 486 (Approx)

Performance:-23.8%

P/L: ₹-238275.9

NIFTY Performance: -2.3%

1 day Top Gainers